# Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT05335356** · PHASE3 · COMPLETED · sponsor: **Biocon Biologics UK Ltd** · enrollment: 384 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Stelara
- **BIOLOGICAL:** Bmab1200

## Key facts

- **NCT ID:** NCT05335356
- **Lead sponsor:** Biocon Biologics UK Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-11-15
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335356, "Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05335356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*